Abstract
Access to detailed three-dimensional structural information on protein drug targets can streamline many aspects of drug discovery, from target selection and target product profile determination, to the discovery of novel molecular scaffolds that form the basis of potential drugs, to lead optimization. The information content of X-ray crystal structures, as well as the utility of structural methods in supporting the different phases of the drug discovery process, are described in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pharmaceutical Manufacturers Association (1993) ‘Facts at a Glance’, Washington DC.
Grabowski, H. J. G. and Vernon, J. M. (1994) Returns to R&D on new drug introductions in the 1980s. J. Health Econ. 13, 282–406.
Gustafsson, D., Byland, R., Antonsson, T., Nilsson, I., Nystrom, J. –E, Eriksson, E., Bredberg, U. and Teger-Nilsson, A. –C. (2004) A new oral anticoagulant: the 50-year challenge. Nature Rev. Drug. Discov. 3, 649–659.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Cryst. 40, 658–674.
Blundell, T. L. and Johnson, L. N. (1976) In Protein Crystallography. Academic Press, New York.
Stout, G. H. and Jensen, L. H. (1989) In X-ray Structure Determination: A Practical Guide. 2nd ed. Wiley, New York.
Drenth J. (1999) In Principles of protein x-ray crystallography. 2nd ed. Springer, New York.
Stout, G. H. and Jensen, L. H. (1989) In X-ray Structure Determination: A Practical Guide. 2nd ed. Wiley, New York, Chapters 7–9.
Winn, M. D., Murshudov G. N. and Papiz, M. Z. (2003) Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374, 300–321.
Drenth J. (1999) In Principles of protein x-ray crystallography. 2nd ed. Springer, New York, pp. 89–90.
Emsley, P. and Cowtan K. (2004) Coot: model-building tools for molecular graphics Acta Cryst. D60, 2126–2132.
Brünger, A. T. (1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472–475.
Jia, Z., Vandonselaar, M., Quail, J. W. and Delbaere, L. T. J. (1993) Active-center torsion-angle strain revealed in 1.6 Å-resolution structure of histidine-containing phosphocarrier protein. Nature 361, 94–97.
Bersio, R., Lazmin, V. S., Sica, F., Wilson, K. S., Zagari, A. and Mazzarella, L. (1999) Protein titration in the crystal state. J. Mol. Biol. 292, 845–854.
Payne, D. J., Gwynn, M. N., Holmes, D. J. and Pompliano, D. L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug. Discov. 6, 29–40.
Champoux, J. J. (2001) DNA topoisomerases: structure, function and mechanism. Annu. Rev. Biochem. 70, 369–413.
Peng, H. and Marians, K. J. (1993) Escherichia coli topoisomerase IV. Purification, characterization, subunit structure and subunit interactions. J. Biol. Chem. 268, 24481–24490.
Wolfson, J. S. and Hooper, D. C. (1985) The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. 28, 581–586.
Oblak, M., Kotnik, M. and Solmajer, T. (2007) Discovery and Development of ATPase Inhibitors of DNA Gyrase as Antibacterial Agents. Curr. Med. Chem. 14, 2033–2047.
Kanehisha, M., Goto, S., Kawashima, S., Okuno, Y. and Hattori, M. (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res. 32, 277–280.
Thompson, J. D., Higgins, D. G. and Gibson, T. J. (1994) CLUSTALW: improving the sensitivity of progressive multiple sequence alignments through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673–4680.
Hann, M.M., Leach, A.R. and Harper, G. (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J.Chem.Inf.Comput.Sci. 41, 856–864.
Labute, P. and Clark A. M. (2007) 2D Depiction of Protein-Ligand Complexes. J. Chem. Inf. Model 47, 1933–1944.
Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J. and Skehel, J. J. (2006) The structure of avian flu neuraminidase suggests new opportunities for drug design. Nature. 443, 45–49.
von-Itzstein, M., Wu, W. Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., Colman, P. M., Varghese, J. N., Ryan, D. M., Woods, R. C., Bethell, R. C., Hotham, V. J., Cameron, J. M and Penn, C. R. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363, 418–423.
(2001) In Physicians’ Desk Reference. 55th ed. Medical Economics Company Inc. Montvale, NJ, p.1454.
Kim, C. U. Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., Laver, W. G. and Stevens, R. C. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active-site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681–690.
Linnekin, D. (1999) Early signaling pathways activated by c-Kit in hematopoietic cells. Int. J. of Biochem. Cell Biol. 31, 1053–1074.
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Tunio, G. M., Matsuzawa, Y., Kanakura, Y., Shinomura, Y. and Kitamura, Y. (1998) Gain of function mutations of c-Kit in human gastrointestinal stromal tumors. Science. 279, 577–580.
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Krause, M. L., Schiebe, D. N., Snell, G. P., Zou, H., Sang, B. –C. and Wilson, K. P. (2004) Structural Basis for the autoinhibition and ST-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279, 31655–31663.
O’Dwyer, M. E., Mauro, M. J., and Druker, B. J. (2003) STI571 as a targeted therapy for CML. Cancer Investig. 3, 429–438.
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J. and Lydon, N. B. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139–145.
Khochbin, S., Verdel, A., Lemercier, C. and Seigneurin-Berny, D. (2001) Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11, 162–166.
Marks, P. A. and Xu, W. S. (2009) Histone-deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 107, 600–608.
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C. D., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., Tang, J., Sang, B. C., Verner, E., Wynands, R., Leahy, E. M., Dougan, D. R., Snell, G., Navre, M., Knuth, M. W., Swanson, R. V., McRee, D. E. and Tari, L. W. (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1–20.
Harris, T. K. and Turner, G. J. (2002) Structural basis of perturbed pKa values of catalytic groups in enzyme active sites. IUBMB Life 53, 85–98.
Dullweber, F., Stubbs, M. T., Musil, D., Sturzebecher, J. and Klebe, G. (2001) Factorising ligand affinity: A combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 313, 593–614.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tari, L.W. (2012). The Utility of Structural Biology in Drug Discovery. In: Tari, L. (eds) Structure-Based Drug Discovery. Methods in Molecular Biology, vol 841. Humana Press. https://doi.org/10.1007/978-1-61779-520-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-61779-520-6_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-519-0
Online ISBN: 978-1-61779-520-6
eBook Packages: Springer Protocols